Post-earnings recap
Reported
Thu, Oct 20, 2011
Est. EPS
—
Est. revenue
—
Implied move
—
EPS beat rate
100%
Boston Scientific's earnings report showed a significant EPS beat, indicating stronger-than-expected profitability. However, the stock fell by 4.4%, likely due to investor concerns about market challenges and the lack of revenue details. The cautious tone from management may have also contributed to the stock's decline.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $0.15 | N/A | +78.57% |
| Revenue | N/A | N/A | N/A |
Overall, management conveyed a cautiously optimistic outlook despite some market challenges. They emphasized the strength of their product portfolio.
Management highlighted strong performance in key product areas.
They noted ongoing challenges in certain markets but expressed confidence in long-term growth.
—
Est. EPS
—
Est. Rev
—
Impl. Move
—